Updated time: 2024-02-29 14:52:53
28A-1090814
2020-09-02
TW I830071、USP Pending
Remdesivir, originally developed by Gilead Sciences, is a broad-spectrum antiviral prodrug of nucleotide with high cell permeability and is a promising therapeutic agent against SARS, MERS, and SARS-CoV-2. The synthetic strategy has several problems, such as low diastereoselectivity and poor yields, which cause significant challenges for manufacture and lead to a high price of drug. The present invention includes the utilization of catalysts to gain a highly diastereoselective phosphoramidation in excellent yield. The present invention provides an efficient and economic route for the production of Remdesivir and its related intermediates in gram scale.
- High yielding diastereoselective phosphoramidation and a mild deprotection method.
- An organocatalyst without heavy metal residue.
- Suitable for production in large scale.
- in process development of Remdesivir and related intermediates in large scale.
- in the synthesis of other phosphoramidate-related prodrugs.

HPLC Chromatogram of Reaction Mixture.
Shang-Cheng Hung, Chi-Huey Wong, Veeranjaneyulu Gannedi, Bharath Kumar Villuri, Nimmakayala Sivakumar Reddy, Chiao-Chu Ku
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Process for the Highly diastereoselective Synthesis of Remdesivir and Intermediates Thereof